~ Progesterone Misconceptions - References
References
1. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005 Jul;96(2):95-108.
2. Stein DG. The case for progesterone. Ann NY Acad Sci. 2005 Jun;1052:152-69.
3. Yen SSC. Endocrine-Metabolic Alterations in Pregnancy. Philadelphia, PA: WB Saunders Co.; 1991:936-981.
4. Andersen CY. Concentrations of free oestradiol and progesterone in human preovulatory follicular fluid. Hum Reprod. 1991 Mar;6(3):359-64.
5. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev. 1990 May;11(2):266-301.
6. Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lignieres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 1995 Apr;63(4):785-91.
7. Heersche JN, Bellows CG, Ishida Y. The decrease in bone mass associated with aging and menopause. J Prosthet Dent. 1998 Jan;79(1):14-6.
8. Dzugan SA, Smith RA. The simultaneous restoration of neurohormonal and metabolic integrity as a very promising method of migraine management. Bull Urg Rec Med. 2003;4(4):622-8.
9. Hotze SF. Hormones, Health, and Happiness. Houston, TX: Forrest Publishing; 2005.
10. Akande EO. Plasma concentration of gonadotrophins, oestrogen and progesterone in hypothyroid women. Br J Obstet Gynaecol. 1975 Jul;82(7):552-6.
11. Dalton, K. The Premenstrual Syndrome and Progesterone Therapy. Chicago, IL: Year Book Medical Publishers; 1977.
12. Lee JR, Zava D, Hopkins V. What Your Doctor May Not Tell You About Breast Cancer. New York, NY: Warner Books; 2002.
13. Huber J. Estrogen substitution therapy in climacteric: should progesterone be omitted in hysterectomized women? Geburtshilfe Frauenheilkd. 1991 Apr;51(4):257-61.
14. Sumino H, Ichikawa S, Itoh H, et al. Hormone replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired and normal glucose tolerance. Horm Res. 2003;60(3):134-42.
15. Kanaya A, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003 Jan 7;138(1):1-9.
16. Chmouliovsky L, Habicht F, James RW, Lehmann T, Campana A, Golay A. Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. Maturitas. 1999 Aug 16;32(3):147-53.
17. Available at: http://www.karger.com/gazette/66/mcewen/art_05.htm. Accessed January 10, 2005.
18. Simoncini T, Mannella P, Fornari L, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology. 2004 Dec; 145(12):5745-56.
19. Beckham JC, Krug LM, Penzien DB, et al. The relationship of ovarian steroids, headache activity and menstrual distress: a pilot study with female migraineurs. Headache. 1992 Jun;32(6):292-7.
20. Smith SS, Waterhouse BD, Chapin JK, Woodward DJ. Progesterone alters GABA and glutamate responsiveness: a possible mechanism for its anxiolytic action. Brain Res. 1987 Jan 6;400(2):353-9.
21. Gulinello M, Smith SS. Anxiogenic effects of neurosteroid exposure: sex differences and altered GABAA receptor pharmacology in adult rats. J Pharmacol Exp Ther. 2003 May;305(2):541-8.
22. Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology. 2003 Feb;28(2):139-68.
23. Le Melledo JM, Baker G. Role of progesterone and other neuroactive steroids in anxiety disorders. Expert Rev Neurother. 2004 Sep;4(5):851-60.
24. Hsu FC, Smith SS. Progesterone withdrawal reduces paired-pulse inhibition in rat hippocampus: dependence on GABA(A) receptor alpha4 subunit upregulation. J Neurophysiol. 2003 Jan;89(1):186-98.
25. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology. 1993 Jun;43(6 Suppl 3):S6-10.
26. Fettes I. Migraine in the menopause. Neurology. 1999;53(4 Suppl 1):S29-33.
27. Silberstein SD, Merriam GR. Sex hormones and headache. J Pain Symptom Manage. 1993 Feb;8(2):98-114.
28. Li W, Zheng T, Altura BM, Altura BT. Sex steroid hormones exert biphasic effects on cytosolic magnesium ions in cerebral vascular smooth muscle cells: possible relationships to migraine frequency in premenstrual syndromes and stroke incidence. Brain Res Bull. 2001 Jan 1;54(1):83-9.
29. Tolsa JF, Gao Y, Raj JU. Developmental change in magnesium sulfate-induced relaxation of rabbit pulmonary arteries. J Appl Physiol. 1999 Nov;87(5):1589-94.
30. O’Shaughnessy A, Muneyyirci-Delale O, Nacharaju VL, et al. Circulating divalent cations in asymptomatic ovarian hyperstimulation and in vitro fertilization patients. Gynecol Obstet Invest. 2001;52(4):237-42.
31. Turner RT, Colvard DS, Spelsberg TC. Estrogen inhibition of periosteal bone formation in rat long bones: down-regulation of gene expression for bone matrix proteins. Endocrinology. 1990 Sep;127(3):1346-51.
32. Turner RT, Backup P, Sherman PJ, Hill E, Evans GL, Spelsberg TC. Mechanism of action of estrogen on intramembranous bone formation: regulation of osteoblast differentiation and activity. Endocrinology. 1992 Aug;131(2):883-9.
33. Barengolts EI, Kouznetsova T, Segalene A, et al. Effects of progesterone on serum levels of IGF-1 and on femur IGF-1 mRNA in ovariectomized rats. J Bone Miner Res. 1996 Oct;11(10):1406-12.
34. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol. 1981 Aug;114(2):209-17.
35. Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci. 1998 Nov-Dec;28(6):360-9.
36. Creasman WT. Hormone replacement therapy after cancers. Curr Opin Oncol. 2005 Sep;17(5):493-9.
37. Medina RA, Meneses AM, Vera JC, et al. Differential regulation of glucose transporter expression by estrogen and progesterone in Ishikawa endometrial cancer cells. J Endocrinol. 2004 Sep;182(3):467-78.
38. De Vivo I, Huggins GS, Hankinson SE, et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci USA. 2002 Sep 17;99(19):12263-8.
39. La Vecchia C, Brinton LA, McTiernan A. Cancer risk in menopausal women. Best Pract Res Clin Obstet Gynaecol. 2002 Jun;16(3):293-307.
40. Southcott BM. Carcinoma of the endometrium. Drugs. 2001;61(10):1395-405.
41. Mahavni V, Sood AK. Hormone replacement therapy and cancer risk. Curr Opin Oncol. 2001 Sep;13(5):384-9.
42. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 1997 Feb 15;349(9050):458-61.
43. Ravn SH, Rosenberg J, Bostofte E. Postmenopausal hormone replacement therapy—clinical implications. Eur J Obstet Gynecol Reprod Biol. 1994 Feb;53(2):81-93.
44. Samsioe G. The endometrium: effects of estrogen and estrogen-progestogen replacement therapy. Int J Fertil Menopausal Stud. 1994;39 Suppl 2:84-92.
45. Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. Br J Cancer. 1996 Jun;73(12):1552-5.
46. Sodi R, Fikri R, Diver M, Ranganath L, Vora J. Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature. Ann Clin Biochem. 2005 Mar;42(Pt 2):153-9.
47. Plourde PV, Reiter EO, Jou HC, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004 Sep;89(9):4428-33.
48. Comhaire F, Mahmoud A. Preventing diseases of the prostate in the elderly using hormones and nutriceuticals. Aging Male. 2004 Jun;7(2):155-69.
49. Tilakaratne A, Soory M. Effects of the anti-androgen finasteride on 5 alpha-reduction of androgens in the presence of progesterone in human gingival fibroblasts: modulatory actions of the alkaline phosphatase inhibitor levamisole. J Periodontal Res. 2000 Aug;35(4):179-85.
50. Available at: www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_06.pdf. Accessed October 4, 2005.
51. Apgar BS, Greenberg G. Using progestins in clinical practice. Am Fam Physician. 2000 Oct 15;62(8):1839-50.
1. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005 Jul;96(2):95-108.
2. Stein DG. The case for progesterone. Ann NY Acad Sci. 2005 Jun;1052:152-69.
3. Yen SSC. Endocrine-Metabolic Alterations in Pregnancy. Philadelphia, PA: WB Saunders Co.; 1991:936-981.
4. Andersen CY. Concentrations of free oestradiol and progesterone in human preovulatory follicular fluid. Hum Reprod. 1991 Mar;6(3):359-64.
5. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev. 1990 May;11(2):266-301.
6. Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lignieres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 1995 Apr;63(4):785-91.
7. Heersche JN, Bellows CG, Ishida Y. The decrease in bone mass associated with aging and menopause. J Prosthet Dent. 1998 Jan;79(1):14-6.
8. Dzugan SA, Smith RA. The simultaneous restoration of neurohormonal and metabolic integrity as a very promising method of migraine management. Bull Urg Rec Med. 2003;4(4):622-8.
9. Hotze SF. Hormones, Health, and Happiness. Houston, TX: Forrest Publishing; 2005.
10. Akande EO. Plasma concentration of gonadotrophins, oestrogen and progesterone in hypothyroid women. Br J Obstet Gynaecol. 1975 Jul;82(7):552-6.
11. Dalton, K. The Premenstrual Syndrome and Progesterone Therapy. Chicago, IL: Year Book Medical Publishers; 1977.
12. Lee JR, Zava D, Hopkins V. What Your Doctor May Not Tell You About Breast Cancer. New York, NY: Warner Books; 2002.
13. Huber J. Estrogen substitution therapy in climacteric: should progesterone be omitted in hysterectomized women? Geburtshilfe Frauenheilkd. 1991 Apr;51(4):257-61.
14. Sumino H, Ichikawa S, Itoh H, et al. Hormone replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired and normal glucose tolerance. Horm Res. 2003;60(3):134-42.
15. Kanaya A, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003 Jan 7;138(1):1-9.
16. Chmouliovsky L, Habicht F, James RW, Lehmann T, Campana A, Golay A. Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. Maturitas. 1999 Aug 16;32(3):147-53.
17. Available at: http://www.karger.com/gazette/66/mcewen/art_05.htm. Accessed January 10, 2005.
18. Simoncini T, Mannella P, Fornari L, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology. 2004 Dec; 145(12):5745-56.
19. Beckham JC, Krug LM, Penzien DB, et al. The relationship of ovarian steroids, headache activity and menstrual distress: a pilot study with female migraineurs. Headache. 1992 Jun;32(6):292-7.
20. Smith SS, Waterhouse BD, Chapin JK, Woodward DJ. Progesterone alters GABA and glutamate responsiveness: a possible mechanism for its anxiolytic action. Brain Res. 1987 Jan 6;400(2):353-9.
21. Gulinello M, Smith SS. Anxiogenic effects of neurosteroid exposure: sex differences and altered GABAA receptor pharmacology in adult rats. J Pharmacol Exp Ther. 2003 May;305(2):541-8.
22. Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology. 2003 Feb;28(2):139-68.
23. Le Melledo JM, Baker G. Role of progesterone and other neuroactive steroids in anxiety disorders. Expert Rev Neurother. 2004 Sep;4(5):851-60.
24. Hsu FC, Smith SS. Progesterone withdrawal reduces paired-pulse inhibition in rat hippocampus: dependence on GABA(A) receptor alpha4 subunit upregulation. J Neurophysiol. 2003 Jan;89(1):186-98.
25. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology. 1993 Jun;43(6 Suppl 3):S6-10.
26. Fettes I. Migraine in the menopause. Neurology. 1999;53(4 Suppl 1):S29-33.
27. Silberstein SD, Merriam GR. Sex hormones and headache. J Pain Symptom Manage. 1993 Feb;8(2):98-114.
28. Li W, Zheng T, Altura BM, Altura BT. Sex steroid hormones exert biphasic effects on cytosolic magnesium ions in cerebral vascular smooth muscle cells: possible relationships to migraine frequency in premenstrual syndromes and stroke incidence. Brain Res Bull. 2001 Jan 1;54(1):83-9.
29. Tolsa JF, Gao Y, Raj JU. Developmental change in magnesium sulfate-induced relaxation of rabbit pulmonary arteries. J Appl Physiol. 1999 Nov;87(5):1589-94.
30. O’Shaughnessy A, Muneyyirci-Delale O, Nacharaju VL, et al. Circulating divalent cations in asymptomatic ovarian hyperstimulation and in vitro fertilization patients. Gynecol Obstet Invest. 2001;52(4):237-42.
31. Turner RT, Colvard DS, Spelsberg TC. Estrogen inhibition of periosteal bone formation in rat long bones: down-regulation of gene expression for bone matrix proteins. Endocrinology. 1990 Sep;127(3):1346-51.
32. Turner RT, Backup P, Sherman PJ, Hill E, Evans GL, Spelsberg TC. Mechanism of action of estrogen on intramembranous bone formation: regulation of osteoblast differentiation and activity. Endocrinology. 1992 Aug;131(2):883-9.
33. Barengolts EI, Kouznetsova T, Segalene A, et al. Effects of progesterone on serum levels of IGF-1 and on femur IGF-1 mRNA in ovariectomized rats. J Bone Miner Res. 1996 Oct;11(10):1406-12.
34. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol. 1981 Aug;114(2):209-17.
35. Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci. 1998 Nov-Dec;28(6):360-9.
36. Creasman WT. Hormone replacement therapy after cancers. Curr Opin Oncol. 2005 Sep;17(5):493-9.
37. Medina RA, Meneses AM, Vera JC, et al. Differential regulation of glucose transporter expression by estrogen and progesterone in Ishikawa endometrial cancer cells. J Endocrinol. 2004 Sep;182(3):467-78.
38. De Vivo I, Huggins GS, Hankinson SE, et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci USA. 2002 Sep 17;99(19):12263-8.
39. La Vecchia C, Brinton LA, McTiernan A. Cancer risk in menopausal women. Best Pract Res Clin Obstet Gynaecol. 2002 Jun;16(3):293-307.
40. Southcott BM. Carcinoma of the endometrium. Drugs. 2001;61(10):1395-405.
41. Mahavni V, Sood AK. Hormone replacement therapy and cancer risk. Curr Opin Oncol. 2001 Sep;13(5):384-9.
42. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 1997 Feb 15;349(9050):458-61.
43. Ravn SH, Rosenberg J, Bostofte E. Postmenopausal hormone replacement therapy—clinical implications. Eur J Obstet Gynecol Reprod Biol. 1994 Feb;53(2):81-93.
44. Samsioe G. The endometrium: effects of estrogen and estrogen-progestogen replacement therapy. Int J Fertil Menopausal Stud. 1994;39 Suppl 2:84-92.
45. Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. Br J Cancer. 1996 Jun;73(12):1552-5.
46. Sodi R, Fikri R, Diver M, Ranganath L, Vora J. Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature. Ann Clin Biochem. 2005 Mar;42(Pt 2):153-9.
47. Plourde PV, Reiter EO, Jou HC, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004 Sep;89(9):4428-33.
48. Comhaire F, Mahmoud A. Preventing diseases of the prostate in the elderly using hormones and nutriceuticals. Aging Male. 2004 Jun;7(2):155-69.
49. Tilakaratne A, Soory M. Effects of the anti-androgen finasteride on 5 alpha-reduction of androgens in the presence of progesterone in human gingival fibroblasts: modulatory actions of the alkaline phosphatase inhibitor levamisole. J Periodontal Res. 2000 Aug;35(4):179-85.
50. Available at: www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_06.pdf. Accessed October 4, 2005.
51. Apgar BS, Greenberg G. Using progestins in clinical practice. Am Fam Physician. 2000 Oct 15;62(8):1839-50.
Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.
While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.
- Life Extension - Life Extension Vitamins
- Metabolism-Garcinia HCA Life Extension
- Glucose Management
- Longevity & Wellness
- Antioxidants
- Body Care
- Bones
- Brain
- Chinese / Mushrooms
- Digestion
- Energy / Sports
- Health Concerns
- Heart / Circulation
- Hormone / Prostate
- Immune
- Inflammatory Factors
- Intimacy
- Liver / Urinary
- Phyto Extracts
- Powdered Supplements
- Seasonal / Respiratory
- Vitamins / Multivitamins / Aminos / Minerals
- Life Extension CoQ10
